RTW Investments, LP and Roderick Wong filed Amendment No. 8 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,537,475 shares of Stoke Therapeutics, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: RTW Investments, LP and Roderick Wong each report beneficial ownership of 6,537,475 shares of Stoke Therapeutics common stock.
- Percent of class: The filing states each reporting person holds 9.99% of the outstanding shares, based on 64,526,242 shares outstanding as of July 30, 2026.
- Shared voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, and 6,537,475 shares each of shared voting and shared dispositive power.
- Warrants included: The share total assumes exercise of warrants to purchase 913,950 shares, the maximum exercisable given a 9.99% beneficial ownership cap under the warrant terms.
- RTW Master Fund Ltd. identified: According to the filing, RTW Master Fund Ltd., an RTW Fund, has the right to receive dividends or proceeds from the sale of more than 5% of the shares.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
RTW Investments and Roderick Wong Disclose Ownership Position in Stoke Therapeutics
RTW Investments, LP, a Delaware limited partnership serving as investment adviser to certain funds referred to in the filing as the "RTW Funds," and Roderick Wong, M.D., the Managing Partner and Chief Investment Officer of RTW Investments, jointly filed Amendment No. 8 to Schedule 13G on November 16, 2026, covering their beneficial ownership position in Stoke Therapeutics, Inc. The filing was triggered by an event dated September 30, 2026, and covers the issuer's common stock, par value $0.0001 per share (CUSIP 86150R107).
According to the filing, the aggregate amount beneficially owned by each reporting person is 6,537,475 shares, representing 9.99% of the class. The percentage is calculated using 64,526,242 shares outstanding as of July 30, 2026, as reported in Stoke Therapeutics' Quarterly Report on Form 10-Q filed with the SEC on August 3, 2026. The filing discloses that the share total assumes the exercise of warrants held by the reporting persons to purchase 913,950 shares, described as "the maximum amount that may be exercised given the current number of outstanding shares and the shares held by the Reporting Persons." The warrant terms prohibit exercise to the extent it would result in beneficial ownership exceeding 9.99% of outstanding shares.
The filing notes that the shares are directly held by the RTW Funds, and that RTW Master Fund Ltd., one of those funds, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the shares. The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Both reporting persons are based at 40 10th Avenue, Floor 7, New York, New York 10014.
What Was Disclosed
RTW Investments, LP and Roderick Wong filed Amendment No. 8 to Schedule 13G reporting beneficial ownership of 6,537,475 shares, or 9.99%, of Stoke Therapeutics, Inc. common stock as of September 30, 2026, including shares attributable to warrants capped at a 9.99% ownership limit.




Please wait processing your request...